TY - JOUR
T1 - Drug-related myopathies of which the clinician should be aware
AU - Valiyil, Ritu
AU - Christopher-Stine, Lisa
N1 - Funding Information:
Acknowledgment Dr. Christopher-Stine’s work is supported by National Institutes of Health grant K23-AR-053197.
PY - 2010/6
Y1 - 2010/6
N2 - Many drugs used for therapeutic interventions can cause unanticipated toxicity in muscle tissue, often leading to considerable morbidity. A drug-induced, or toxic, myopathy is defined as the acute or subacute manifestation of myopathic symptoms such as muscle weakness, myalgia, creatine kinase elevation, or myoglobinuria that can occur in patients without muscle disease when they are exposed to certain drugs. A brief review of agents with a known association with myotoxicity and the proposed mechanisms linked to that toxicity is outlined; however, the purpose of this review is to highlight recent discoveries and advances in the field of toxic myopathies that have practical implications for practicing physicians. Because many drug-related myopathies are potentially reversible at early stages, it is important for clinicians to recognize toxic myopathies early in their course to determine when to discontinue therapy and potentially prevent irreversible muscle damage.
AB - Many drugs used for therapeutic interventions can cause unanticipated toxicity in muscle tissue, often leading to considerable morbidity. A drug-induced, or toxic, myopathy is defined as the acute or subacute manifestation of myopathic symptoms such as muscle weakness, myalgia, creatine kinase elevation, or myoglobinuria that can occur in patients without muscle disease when they are exposed to certain drugs. A brief review of agents with a known association with myotoxicity and the proposed mechanisms linked to that toxicity is outlined; however, the purpose of this review is to highlight recent discoveries and advances in the field of toxic myopathies that have practical implications for practicing physicians. Because many drug-related myopathies are potentially reversible at early stages, it is important for clinicians to recognize toxic myopathies early in their course to determine when to discontinue therapy and potentially prevent irreversible muscle damage.
KW - Drug-induced myopathy
KW - Statin myopathy
KW - Toxic myopathy
UR - http://www.scopus.com/inward/record.url?scp=77953449990&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953449990&partnerID=8YFLogxK
U2 - 10.1007/s11926-010-0104-3
DO - 10.1007/s11926-010-0104-3
M3 - Review article
C2 - 20425521
AN - SCOPUS:77953449990
SN - 1523-3774
VL - 12
SP - 213
EP - 220
JO - Current rheumatology reports
JF - Current rheumatology reports
IS - 3
ER -